MP Materials vs ResMed Inc. — how do they compare? MP Materials trades at $54.53 (market cap $9.86B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 3.2× MP Materials's market cap, and ResMed Inc. pays a 1.19% dividend while MP Materials pays none. Which is the better fit depends on your goals.
| MP | RMD | |
|---|---|---|
Market Cap | $9.86B | $31.89B |
Sector | Industrials | Health |
52-Week High | $98.65 | $283.28 |
52-Week Low | $38.10 | $182.82 |
Enterprise Value | $9.34B | $31.24B |
Dividend Yield | — | 1.19% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Trailing returns across standard periods
MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.
Read more on MP →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →